Tenaya Therapeutics, Inc. (TNYA) — insider trading
Health Care · NASDAQ
Tenaya Therapeutics, Inc. (TNYA) has 23 reported SEC Form 4 insider transactions in our data, including 11 open-market sales among the most recent 23 (latest 2026-09-10).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-10 | Tingley Whittemore | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 293,000 | — | $0 | Form 4 |
| 2026-09-10 | Tingley Whittemore | Officer (Chief Medical Officer) | Grant / award / vesting | 49,000 | — | $0 | Form 4 |
| 2026-09-10 | Ali Faraz | Director, Officer (Chief Executive Officer) | Grant / award / vesting (derivative) | 732,500 | — | $0 | Form 4 |
| 2026-09-10 | Ali Faraz | Director, Officer (Chief Executive Officer) | Grant / award / vesting | 122,000 | — | $0 | Form 4 |
| 2026-08-17 | Tingley Whittemore | Officer (Chief Medical Officer) | Open-market sale | 2,279 | $0.7098 | $1.6K | Form 4 |
| 2026-08-17 | Tingley Whittemore | Officer (Chief Medical Officer) | Open-market sale | 1,871 | $0.7098 | $1.3K | Form 4 |
| 2026-08-17 | Tingley Whittemore | Officer (Chief Medical Officer) | Open-market sale | 1,637 | $0.7098 | $1.2K | Form 4 |
| 2026-08-17 | Tingley Whittemore | Officer (Chief Medical Officer) | Open-market sale | 1,637 | $0.7098 | $1.2K | Form 4 |
| 2026-08-17 | Ali Faraz | Director, Officer (Chief Executive Officer) | Open-market sale | 7,406 | $0.7097 | $5.3K | Form 4 |
| 2026-08-17 | Ali Faraz | Director, Officer (Chief Executive Officer) | Open-market sale | 5,020 | $0.7097 | $3.6K | Form 4 |
| 2026-08-17 | Ali Faraz | Director, Officer (Chief Executive Officer) | Open-market sale | 3,969 | $0.7098 | $2.8K | Form 4 |
| 2026-08-17 | Ali Faraz | Director, Officer (Chief Executive Officer) | Open-market sale | 5,837 | $0.7097 | $4.1K | Form 4 |
| 2026-07-13 | Hyllengren Eric J | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 1,650,000 | — | $0 | Form 4 |
| 2026-05-28 | Burroughs Amy L. | Director | Grant / award / vesting (derivative) | 120,000 | — | $0 | Form 4 |
| 2026-05-28 | Lee June | Director | Grant / award / vesting (derivative) | 120,000 | — | $0 | Form 4 |
| 2026-05-28 | Parschauer Karah Herdman | Director | Grant / award / vesting (derivative) | 120,000 | — | $0 | Form 4 |
| 2026-05-28 | Srivastava Deepak | Director | Grant / award / vesting (derivative) | 120,000 | — | $0 | Form 4 |
| 2026-05-28 | Stehman-Breen Catherine | Director | Grant / award / vesting (derivative) | 120,000 | — | $0 | Form 4 |
| 2026-05-28 | Walsh Jeffrey T. | Director | Grant / award / vesting (derivative) | 120,000 | — | $0 | Form 4 |
| 2026-05-28 | Williams R Sanders | Director | Grant / award / vesting (derivative) | 120,000 | — | $0 | Form 4 |
| 2026-05-18 | Higa Tomohiro | Officer (SVP, Finance) | Open-market sale | 1,485 | $0.7932 | $1.2K | Form 4 |
| 2026-05-18 | Tingley Whittemore | Officer (Chief Medical Officer) | Open-market sale | 3,121 | $0.7936 | $2.5K | Form 4 |
| 2026-05-18 | Ali Faraz | Director, Officer (Chief Executive Officer) | Open-market sale | 3,390 | $0.7934 | $2.7K | Form 4 |
Ask the chat about TNYA's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Tenaya Therapeutics, Inc. (TNYA).
Last updated 2026-09-10 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.